Quick Answer
Coenzyme Q10 Exercise Recovery Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT).
Key Takeaways
- 01Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT). [Wan Q (2026)]
- 02Moderate-intensity aerobic and resistance exercise consistently improved maximal oxygen uptake (VO 2 max), maximal workload (W max), muscle strength, and mitochondrial enzyme activity, with no consistent group-level increases observed in creatine kinase (CK) levels or mtDNA mutation burden. [Wan Q (2026)]
- 03Aerobic training enhanced oxidative capacity, phosphocreatine (PCr) recovery, and antioxidant defense, while resistance training improved muscle strength, satellite cell activation, and reduced cytochrome c oxidase (COX)-deficient fibers. [Wan Q (2026)]
- 04Background Mitochondrial myopathy (MM) is a group of rare, progressive muscle disorders characterized by impaired oxidative phosphorylation due to mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations, leading to exercise intolerance, muscle weakness, and metabolic dysfunction. [Wan Q (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coenzyme Q10 Exercise Recovery Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT). [Wan Q (2026); evidence level 1]
- Moderate-intensity aerobic and resistance exercise consistently improved maximal oxygen uptake (VO 2 max), maximal workload (W max), muscle strength, and mitochondrial enzyme activity, with no consistent group-level increases observed in creatine kinase (CK) levels or mtDNA mutation burden. [Wan Q (2026); evidence level 1]
- Aerobic training enhanced oxidative capacity, phosphocreatine (PCr) recovery, and antioxidant defense, while resistance training improved muscle strength, satellite cell activation, and reduced cytochrome c oxidase (COX)-deficient fibers. [Wan Q (2026); evidence level 1]
- Background Mitochondrial myopathy (MM) is a group of rare, progressive muscle disorders characterized by impaired oxidative phosphorylation due to mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations, leading to exercise intolerance, muscle weakness, and metabolic dysfunction. [Wan Q (2026); evidence level 1]
- The results demonstrated that oral coenzyme Q10 elevated blood coenzyme Q10 concentration (standardized mean difference: 2.710, 95% confidence interval: 1.57-3.85, p < 0.00001) and reduced blood malondialdehyde concentration (standardized mean difference: -0.289, 95% confidence interval: -0.541 to -0.038, p = 0.024). [Zhang Y (2026); evidence level 1]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources